Schnelle 50 % Chance nach Panikverkauf !

SCHNELLE 50 % Gewinn nach Panikartigen Gewinnmitnahmen und StoppLoss Orders !

 

 

WKN 694271

 

genau erkundigen bevor man kauft -  

.....sieht in meinen Augen nach einem weiteren Kursverfall aus....!!

http://finance.yahoo.com/news/...eet-cnw-2965005701.html?x=0&.v=1

 

Ist halt ein Zocker Wert, und auch nur Zocker sollten da ran gehen.

... (automatisch gekürzt) ...

Nachrichten lesen - dann weißt Du mehr -
auf jeden Fall - Nein Danke  

hat gekauft und will wieder verkaufen, schätze ich mal.....

Aber wenn er sich da nicht mal die Finger verbrennt.....

Nur warum andere mitreißen?  

...der 1 Jahres Chart bei Ariva sieht so aus als wenn das Teil noch bei 1,30 Euro steht.
Dabei ist das Teil ja bei 0,88 Cent.
D.h. weit unter Nov. Jahrestief.
Finger weg - fallendes Messer.!!!!!

@dzi67 Du hast bestimmt Recht mit den Nachrichten lesen. Der Sturz hat bestimmt fundamente Gründe.
Wenn mir aber der Chart schon nicht gefällt spar ich mir das fundamentale.
Denn im Kurs sind bereits alle relevanten Faktoren eingepreisst.

Gruß BörsenBoom

Entwickler in der Behandlung der Multiplen Sklerose (MS)

zuschalgen oder geht das Ding noch weiter nach unten? 0,17

was meint Ihr????  

...mit der Zockaktie.
Vor 2 Stunden noch minus 50 Prozent, und jetzt minus 88 Prozent.
Hoffentlich ist da niemand mit rein, denn schneller konnte man sein Geld nicht vernichten.

@pach11

Mein Tipp: Laß die Finger davon.
Natürlich kanns auf 0,30 hoch gehen, aber auch auf 0,08.
Glaube mir wenn Du es 3 mal machst hast Du aber 2 mal danebengelegen,
denn solche Zockaktien gehen eher runter als hoch.
Ist aber Deine Entscheidung.

Gruß BörsenBoom

Was ist los mit der schrottaktie ? Muss mal News lesen ....

MFG
Chali  

 

 

Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial
In Secondary Progressive Multiple Sclerosis 

INDIANAPOLIS, Indiana and EDMONTON, Alberta, July 27, 2009 – Eli Lilly and Company (NYSE: LLY) and BioMS Medical Corp. (TSX: MS) today announced that dirucotide did not meet the primary endpoint of delaying disease progression, as measured by the Expanded Disability Status Scale (EDSS), during the two-year MAESTRO-01 Phase III trial in patients with secondary progressive multiple sclerosis (SPMS). In addition, there were no statistically significant differences between dirucotide and placebo on the secondary endpoints of the study.

The data also showed that dirucotide was generally well tolerated. There were no unexpected safety or tolerability issues. The most common side effect reported was injection site reaction. More details of the MAESTRO-01 study results are expected to be presented at a medical conference later this year.

Lilly and BioMS also announced they would discontinue ongoing clinical trials – including MAESTRO-02 and MAESTRO-03 – and review the available data from these studies. MAESTRO-02 is an open-label follow-on study to MAESTRO-01. MAESTRO-03 is a 510-patient U.S. Phase III clinical trial designed to evaluate dirucotide for the treatment of SPMS that completed enrollment in August 2008. Lilly and BioMS will inform regulatory agencies and provide instructions to investigators outlining the process for discontinuing the studies. Patients involved in studies who have questions should contact their study investigator.

“The MAESTRO-01 study was well designed and executed, and we believe these data, while disappointing, are very instructive for us and for the larger MS community,” said John Hayes, vice president of Lilly Research Laboratories. “We look forward to further conversations with BioMS Medical about this project.”

"We are obviously disappointed by this result and will be working closely with our clinical team to evaluate these data and the available data from MAESTRO-02 and MAESTRO-03 to determine our next steps,” said Kevin Giese, President and CEO of BioMS Medical. "We are fortunate to have suitable resources in place to remain flexible to pursue whatever options emerge once we understand these results more fully.”

BioMS Medical Webcast
Participants may listen to a discussion of the outcome of the MAESTRO-01 study by Kevin Giese, President and CEO of BioMS Medical. The audio webcast is accessible through the Company’s web site at www.biomsmedical.com.

About MAESTRO-01
MAESTRO-01 was a multi-center, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of dirucotide in patients with SPMS. The study was conducted in Canada and nine countries in Europe and included 612 patients being administered either dirucotide or placebo intravenously every six months for a period of two years.

The primary clinical endpoint for the trial was defined as a statistically significant increase in the time to progression of the disease, as measured by the EDSS, in patients with HLA-DR2 and/or HLA-DR4 immune response genes. It is estimated that up to 70% of all multiple sclerosis patients are HLA-DR2 and/or HLA-DR4 positive. The EDSS is the standard for measuring impairment in MS.

About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, progressive, often disabling disease that attacks the central nervous system. MS is caused by damage to myelin, the protective sheath surrounding nerve fibers in the central nervous system, resulting in disrupted nerve impulses traveling to and from the brain and spinal cord. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis.iii,

MS is thought to affect as many as 2.5 million people worldwide, including approximately 400,000 in the United States. It is a disease that affects more women than men, with onset typically occurring between 20 and 50 years of age.v

Approximately 30-40 percent of all MS patients have the secondary progressive form of the disease, in which irreversible disability accumulates more steadily, with or without relapses. There are few treatment options available for these patients.

About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

 

www.biomsmedical.com/display-press-release.php

 

 

 

 

waren 50 % Minus möglich..... war das so gemeint? loool  

Münchhausen bespricht niemals Aktien, die nach seiner Posaunerei wieder - mangels Substanz - abstürzen.
Für bioms hatte er gewaltig getrommelt. Jetzt nichts mehr.
Da 90 % Verlust für seine Aktien keine Seltenheit sind, könnte bio weiter abstürzen.
Aber letztlich behält er doch immer Recht. Also, kaufen, kaufen, kaufen.